<DOC>
	<DOCNO>NCT01547715</DOCNO>
	<brief_summary>This study evaluate immunogenicity single injection Novartis Meningococcal ACWY conjugate vaccine healthy subject age 2 year India .</brief_summary>
	<brief_title>Immunogenicity Safety Meningococcal ACWY Conjugate Vaccine Healthy Subjects From 2 75 Years Age India</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Bacterial</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Individuals eligible enrollment study : 1. gender , age 2 75 year time visit 1 , nature study explain : parent/legal representative provide write informed consent ( great equal 2 less 18 year age ) . provide write assent ( great equal 7less equal 18 year ) provide write informed consent ( great equal 18 75 year age ) . 2. investigator believe parents/legal representative comply requirement protocol ( e.g. , completion Diary Card , return followup visit ) . 3. good health determine medical history , physical exam , clinical judgment investigator 4. negative urine pregnancy test female subject childbearing potential . Individuals eligible enrol study : 1. unwilling unable give write informed assent consent participate study . 2. perceive unreliable unavailable duration study period . 3. previous suspect disease cause N. meningitidis . 4. household contact and/or intimate exposure individual cultureproven N. meningitidis infection within 60 day prior enrollment . 5. previously immunize meningococcal vaccine . 6. receive investigational nonregistered product ( drug vaccine ) within 28 day prior enrollment expect receive investigational drug vaccine prior completion study . 7. receive vaccine within 14 day ( inactivated vaccine ) 28 day ( live vaccine ) prior enrollment study plan receive vaccine within 30 day study vaccine . ( Exception : Influenza vaccine may administer 15 day prior study vaccination least 15 day study vaccination ) 8. experience within 7 day prior enrollment significant acute infection ( example require systemic antibiotic treatment antiviral therapy ) experience fever ( define body temperature great equal 38Â°C ) within 3 day prior enrollment . 9. serious acute , chronic progressive disease ( e.g. , history neoplasm , cancer , diabetes , cardiac disease , autoimmune disease , HIV infection AIDS , blood dyscrasia , sign cardiac renal failure severe malnutrition ) . 10. epilepsy progressive neurological disease . 11. history anaphylaxis , serious vaccine reaction , allergy vaccine component . 12. know suspected impairment/alteration immune function , either congenital acquire result ( example ) : receipt immunosuppressive therapy within 28 day prior enrollment ( systemic corticosteroid administer 5 day , daily dose great 1 mg/kg/day prednisone equivalent 28 day prior enrollment , cancer chemotherapy ) receipt immunostimulants receipt parenteral immunoglobulin preparation , blood product , and/or plasma derivative within 90 day prior enrollment full length study . 13. known bleed diathesis , condition may associate prolonged bleeding time . 14. condition , opinion investigator , might interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Meningococcal ,</keyword>
	<keyword>ACWY ,</keyword>
	<keyword>bacterial meningitis ,</keyword>
	<keyword>conjugate vaccine ,</keyword>
	<keyword>healthy , child ,</keyword>
	<keyword>adolescent ,</keyword>
	<keyword>adult ,</keyword>
	<keyword>India</keyword>
</DOC>